Results 141 to 150 of about 15,564 (249)

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration [PDF]

, 2018
Bryan Smith, Andrea Kießling, Rocío Lledó‐García, Kate L. Dixon, Louis Christodoulou, Matthew C. Catley, Paul Atherfold, Lena E. D’Hooghe, Helene M. Finney, Kevin Greenslade, Hanna Hailu, Lara Kevorkian, Daniel Lightwood, Christoph Meier, Rebecca Munro, Omar Qureshi, Kaushik Sarkar, Sophie P. Shaw, Roohi Tewari, Alison Turner, Kerry Tyson, Shauna West, Stevan Shaw, Frank R. Brennan   +23 more
openalex   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 796-806, April 2026.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1036-1046, April 2026.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu, Farina Hellmann, Xiaowei Zang, Nele Plock, Keyur Parmar, Radha A. Railkar, S. Y. Amy Cheung, Brian M. Maas, Ferdous Gheyas   +8 more
wiley   +1 more source

Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety.
Hammad Javaid, Maria Qadri, Hameer Ali, Chika Franklin Chilaka, Wajiha Syed, Erum Habib, Fahmida Zahin, Ayaan Musani, Salauddin Ali Khan, Daniah Rizwan, Muhammad Nabeel Saddique, Fatima Hajj   +11 more
wiley   +1 more source

FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques

mAbs
Prenatal administration of monoclonal antibodies (mAbs) is a strategy that could be exploited to prevent viral infections during pregnancy and early life.
Joanna Zikos, Gabriela M. Webb, Helen L. Wu, Jason S. Reed, Jennifer Watanabe, Jodie L. Usachenko, Ala M. Shaqra, Celia A. Schiffer, Koen K. A. Van Rompay, Jonah B. Sacha, Diogo M. Magnani   +10 more
doaj   +1 more source

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models [PDF]

, 2020
Delphine Valente, Christine Mauriac, Thorsten Schmidt, Ingo Focken, Jochen Beninga, Brian C. Mackness, Huawei Qiu, Pascale Vicat, Abdullah Kandira, Katarina Radošević, Srini Rao, John F. Darbyshire, Mostafa Kabiri   +12 more
openalex   +1 more source

Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight‐Based to Flat‐Dosing Strategy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
ABSTRACT Serplulimab is a fully humanized anti–PD‐1 monoclonal antibody approved for small‐cell lung cancer and other malignancies. The initial dosing strategy was based on body weight (WT‐based); however, flat‐dosing offers greater convenience and reduced variability.
Kun Wang, Yuanyuan Shen, Chen Hu, Fengyan Xu, Zhihao Kwok, Qingyu Wang, Yaqi Lin, Yuying Gao, Liang Zhou   +8 more
wiley   +1 more source

FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines

npj Vaccines
Dendritic cell (DC)-targeted vaccination is a new mode of antigen delivery that relies on the use of monoclonal antibodies (mAb) to target antigen to specific DC subsets.
Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille H. Lahoud, Jose A. Villadangos, Justine D. Mintern   +9 more
doaj   +1 more source

Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients [PDF]

, 2022
Sindhu Ramchandren, Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gámez, Sven G. Meuth, Richard M. Nowak, Dianna Quan, Maria Teresa Sevilla Mantecon, Leona Ling, Yaowei Zhu, Keith Karcher, Hong Sun   +12 more
openalex   +1 more source

Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

European Journal of Neurology, Volume 33, Issue 4, April 2026.
C5‐inhibition may represent an effective adjunctive treatment in therapy‐refractory myasthenic crisis, including thymoma‐associated MG (TAMG). ABSTRACT Introduction Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation.
Lea Gerischer, Maike Stein, Alice Schneider, Hanna Tangen, Johanna Loris, Stefanie Glaubitz, Jana Zschüntzsch, Ulrich Hofstadt‐van Oy, Charlotte Schubert, Christoph Heesen, Melina Schlag, Tim Hagenacker, Menekse Oeztuerk, Tobias Ruck, Paolo Doksani, Carla Dusemund, Meret Herdick, Julia Herzig‐Nichtweiß, Philipp Mergenthaler, Frauke Stascheit, Amani Suboh, Lisa Schwarz, Sarah Hoffmann, Andreas Meisel, Sophie Lehnerer   +24 more
wiley   +1 more source